Diagnostic-driven therapies are being discovered and developed faster than ever, yet too many eligible patients never receive the treatments that could help them.
Today, due to complex diagnostic workflows, evolving testing protocols, and structural access barriers across care settings, eligible patients are frequently lost along the treatment journey. This is not a failure of science—it is a breakdown in care pathways and commercial execution. It's also an increasingly common problem for in-market therapies, as well as new and emerging ones.
In one example, Diaceutics published research has shown that in advanced non-small cell lung cancer (aNSCLC), a disease where targeted therapy exists and should be benefiting patients, approximately 64% of eligible patients do not receive the appropriate targeted therapy. Roughly 29% are lost from the pathway even after a diagnostic test has successfully identified the actionable biomarker.
Closing these gaps requires a new commercialization model, one that helps biopharma teams strengthen diagnostic readiness, improve testing consistency and availability, educate healthcare providers and connect eligible patients with the right treatment.
Diagnostic-driven therapies are therapies where diagnostic activity influences whether, when, or how patients reach treatment. In other words, they are therapies where diagnostic intelligence creates a competitive advantage.
How to Close the Gaps
Science has already transformed what's possible. What's been missing is a commercialization model built explicitly to match it—and the collective will to change. Now is the time for the industry to address these gaps, ensuring that more patients receive the therapy they need.
Closing the gap doesn't require a bigger version of the old model—it requires a different one.
First, persistent practice gaps must be identified in real time, using real-world data and insights to see exactly where and why patients are being lost across the pathway.
Secondly, diagnostic infrastructure—laboratories and testing networks—must be supported to reduce variability in ordering, panels, and turnaround times.
Thirdly, treating clinicians must be given clear, contextual support at the moment intention becomes action.
This isn’t an aspirational model, it’s already in place. Diaceutics has made a positive impact on engagement and interventions for a wide range of brands across numerous therapy areas, pre-launch (36%), launch (20%) and 3 years post launch (44%).
For example, Diaceutics has shown that a program of precision outreach and real-world data can transform rare disease management for a childhood rare disease. By enabling timely engagement with physicians, Diaceutics helped accelerate therapy adoption for an in-market therapy, improve patient access, and support more equitable care for a highly underserved population. The program identified 121 patients eligible for a therapy, generating $2M in revenue and a 70% ROI.
Across its work with biopharma companies, these approaches have delivered a 35% uplift in new therapy starts, an 8% increase in market share within 12 months for a top 10 pharmaceutical company, and a 19% increase in actionable care targets. These results demonstrate what is possible when diagnostic, commercial, medical, and market access functions work from a shared understanding of where patients are being lost and how to close those gaps.
Turn diagnostic intelligence into commercial action
This is the model Diaceutics has built its Intelligence and Engagement Solutions around. Powered by Diaceutics' Reveal data engine, its solutions connect real-world diagnostic activity with the intelligence and engagement to see where eligible patients are being missed, act while treatment decisions are forming and help more people reach the right therapy.
- Intelligence Solutions uncover where diagnostic activity is creating opportunity—where patients are being missed, which HCPs shape care, and which labs can change the pathway.
- Engagement Solutions help reach the people who can move that pathway forward—through targeted HCP marketing, scientific exchange and lab engagement at the moment that matters.
The shift these solutions enable is important: from looking retrospectively at what happened, to acting prospectively on what's happening now.
Diaceutics: Life unlocked
Diaceutics is the intelligence and engagement company unlocking the full potential for diagnostic-driven therapies. It helps biopharma teams find eligible patients earlier, understand where diagnostic pathways break down, and act while treatment decisions are still forming.
Diaceutics has spent more than 20 years working at the intersection of diagnostics and commercialization and today works with biopharma companies ranging from emerging biotech to 21 of the world's top 30 pharma companies.
Precision for All
Science has given us the ability to identify increasingly precise patient populations and develop therapies specifically for them. The next challenge is ensuring our commercialization models are equally precise.
That's the ambition behind Precision for All: a future where every eligible patient is identified, diagnosed and receives the right therapy at the right time.
Getting there will require biopharma, diagnostics, HCPs, labs, and health systems to close the gaps between innovation and impact together. The technology, data and expertise exist, the opportunity now is to put them to work.
It's time to make precision the standard for all, not the privilege of the few.
Join us to close the gap between innovation and impact:
